<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02446977</url>
  </required_header>
  <id_info>
    <org_study_id>JCS-CBG-2014-01</org_study_id>
    <nct_id>NCT02446977</nct_id>
    <nct_alias>NCT02540980</nct_alias>
  </id_info>
  <brief_title>Administration of CBG000592 (Riboflavin/Vitamin B2) in Patients With Acute Ischemic Stroke</brief_title>
  <official_title>Randomized Clinical Trial to Investigate Whether Administration of CBG000592 (Riboflavin/Vitamin B2) in Patients With Acute Ischemic Stroke Causes a Reduction of Glutamate-mediated Excitotoxicity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Castillo, José, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Castillo, José, M.D.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Administration of CBG000592 (riboflavin/vitamin B2) in patients with acute ischemic stroke to
      know if it causes a reduction of glutamate-mediated excitotoxicity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators hypothesis focuses on the effect of riboflavin given for the first three
      hours of ischemic stroke, as a reducing agent of cerebral glutamate concentration. This
      administration would produce a reduction of excitotoxic damage and consequently generate
      clinical improvement, while a lower income and a better functional outcome of patients at
      three months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of serum glutamate concentration</measure>
    <time_frame>7 hours</time_frame>
    <description>Difference between serum glutamate concentration from basal (prior to medication infusion) and levels at 3 ± 1 and 6 ± 1 hours, from administered medication, including branch CBG000592 (riboflavin/vitamin B2) and placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Days of hospitalisation</measure>
    <time_frame>3 months</time_frame>
    <description>To study the average length of stay in patients with acute ischemic stroke: difference in days, between patient arrival and the patient's discharge, between the two treatment arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of clinical improvement (basal-high)</measure>
    <time_frame>3 months</time_frame>
    <description>To study the rate of clinical improvement in patients with acute ischemic stroke: clinical improvement according to the formula: (NIHSSbasal-NIHSSalta) / NIHSSbasal x 100 and compared between the two treatment arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional outcome using Rankin Scale at 90 days</measure>
    <time_frame>3 months</time_frame>
    <description>Study the functional outcome in patients with acute ischemic stroke: modified Rankin scale at 90 days, between two treatment arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum glutamate concentrations</measure>
    <time_frame>7 hours</time_frame>
    <description>Variations of serum glutamate curves in patients with acute ischemic stroke between two branches: all concentrations of serum glutamate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognosis of patients using Rankin Scale at 90 days</measure>
    <time_frame>3 months</time_frame>
    <description>To explore the prognosis of patients without stroke, evaluating modified Rankin scale at 90 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Adverse Event</measure>
    <time_frame>3 months</time_frame>
    <description>Safety management: measuring adverse events throughout the study.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Vitamin B2 Streuli®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20mg IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Solution for injection</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4ml IV</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin B2 Streuli®</intervention_name>
    <description>4ml IV</description>
    <arm_group_label>Vitamin B2 Streuli®</arm_group_label>
    <other_name>CBG000592</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Solution for injection</intervention_name>
    <description>4ml IV</description>
    <arm_group_label>Solution for injection</arm_group_label>
    <other_name>Placebo Comparator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients older than 18 years, both men and women.

          2. Patient or legal representative able to understand and sign the informed consent.

          3. Patients with suspected stroke within 3 hours of onset.

        Exclusion Criteria:

          1. Women of childbearing age, with potential for pregnancy or breastfeeding.

          2. Patients with a score ≥ 2 point 1a in the NIHSS scale.

          3. Scale pre-stroke modified Rankin ≥ 2.

          4. Inability to prior testing image needed for the study.

          5. Previous disorders that may interfere with the interpretation of neurological scales.

          6. Treatment with probenecid, tricyclic antidepressants, phenothiazines, streptomycin,
             erythromycin, tyrothricin, tetracyclines and carbomycin, at the time of inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>José Castillo, MD</last_name>
    <role>Study Director</role>
    <affiliation>Complejo Hospitalario Universitario de Santiago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>A Coruña</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2015</study_first_submitted>
  <study_first_submitted_qc>May 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2015</study_first_posted>
  <last_update_submitted>October 12, 2016</last_update_submitted>
  <last_update_submitted_qc>October 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ischemic</keyword>
  <keyword>stroke</keyword>
  <keyword>vitamin B2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Riboflavin</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

